Objective We systematically reviewed the literature on COVID-19 in patients with multiple
sclerosis (MS). Methods We searched PubMed, Scopus, EMBASE, CINAHL, Web of …

People with multiple sclerosis (MS) are at risk for infections that can result in amplification of
baseline symptoms and possibly trigger clinical relapses. Vaccination can prevent infection …

Background and Objectives To report safety of ocrelizumab (OCR) up to 7 years in patients
with relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) …

CD20 depletion is a risk factor for unfavorable outcomes of COVID-19 in people with MS
(pwMS). Evidence suggests that protective IgG response to mRNA-based vaccines in B cell …

Background Recent data on the rates of infections among patients with multiple sclerosis
(MS) are sparse. The objective of this study was to quantify incidence of infections in patients …

Objective To determine whether the course of COVID-19 is more severe in patients with MS
and if MS disease-modifying treatments (DMTs) affect the risk of contracting the disease …

Background: Little is known about infection risk in multiple sclerosis (MS). Objective: We
examined infection-related health care utilization in people with and without MS. Methods …

The progress in the development of various vaccine platforms against SARS-CoV-2 have
been rather remarkable owing to advancement in molecular and biologic sciences. Most of …

Aims To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort
of multiple sclerosis (MS) patients receiving different immunomodulating …

Objective To identify risk factors for an increased lethality of COVID-19 in patients with
multiple sclerosis (MS). Methods We searched scientific databases to identify cohort studies …